Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 955 of 6351
-
New pill shows promise for fatty liver in major trial
Disease control OngoingA 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Phase 3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a drug combo stop smoldering myeloma in its tracks?
Disease control Recruiting nowThis phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with …
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a transplant drug stop COVID lung damage?
Disease control OngoingThe primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.
Phase 2/3 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Triple drug cocktail targets tough leukemia
Disease control Recruiting nowThis phase I/II trial studies the best dose of gilteritinib given together with ASTX727 and venetoclax and the effect of ASTX727, venetoclax, and gilteritinib in treating patients with FLT3-mutated acute myeloid leukemia that is newly diagnosed, has come back (relapsed) or does n…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New chemo cocktail aims to stop colon Cancer's return
Disease control Recruiting nowA multicenter, open labeled randomized, phase II trial comparing mFOLFIRINOX and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer
Phase 2/3 • Sponsor: Chungnam National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for pancreatic cancer recurrence: targeted radiation trial underway
Disease control Recruiting nowA randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'trials within cohorts' (TwiCs) design in which the effect of additional local ablative therapy compared to current standard of care alone, on sur…
Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New vaccine aims to train immune system against lymphoma
Vaccine Recruiting nowThe purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Phase 1/2 • Sponsor: Enterome • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
New pill shows promise against Hard-to-Treat HER2 cancers
Disease control OngoingThe study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutatio…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can an HIV drug help beat lung cancer? new trial aims to stop resistance
Disease control Recruiting nowThis phase II trial studies the effect of lamivudine in combination with standard of care chemoimmunotherapy in treating patients with extensive stage small cell lung cancer. Even though small cell lung cancer is initially highly responsive to first-line chemotherapy treatment, t…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug cocktail aims to tackle tough lymphoma
Disease control Recruiting nowThis research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib…
Phase 1/2 • Sponsor: Austin I Kim • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a brain implant learn to sense OCD distress and respond in real time?
Disease control OngoingThis research study is for participants that have been diagnosed with intractable Obsessive -compulsive disorder (OCD). OCD is a persistent and oftentimes disabling disorder marked by unwanted and distressing thoughts (obsessions) and irresistible repetitive behaviors. OCD affect…
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New trial aims to delay prostate cancer progression with targeted local therapy
Disease control Recruiting nowThis is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with o…
Phase 2/3 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy aims to boost survival in tough esophageal cancer cases
Disease control OngoingTislelizumab combined with chemotherapy sequential neoadjuvant therapy for non-cCR patients after neoadjuvant chemoradiotherapy in locally advanced ESCC. And then the patients would receive surgery and adjuvant therapy according to the postoperative pathological results. It is ex…
Phase 2 • Sponsor: Sichuan Cancer Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Gene therapy aims to free patients from daily steroids for rare adrenal disorder
Disease control OngoingThis study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.
Phase 1/2 • Sponsor: Adrenas Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New radiation approach targets lung cancer leftovers without more surgery
Disease control Recruiting nowTo prospectively evaluate the effectiveness and safety of SBRT in the treatment of residual malignant pulmonary nodules after lung cancer, and is committed to providing new treatment options for patients with multiple primary malignant pulmonary nodules who cannot tolerate multip…
Sponsor: Fang Wu • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Hospital study aims to slash surgical infections by 88%
Prevention OngoingSurgical site infections (SSIs) are associated with increased patient morbidity, mortality, and healthcare costs. ESKAPE (Enterococcus, S. aureus, Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter spp.) pathogens are particularly pathogenic because they have increased capa…
Sponsor: Trustees of Dartmouth College • Aim: Prevention
Last updated Jul 10, 2026 00:00 UTC
-
Swallow a sponge to detect esophageal cancer? new study investigates
Diagnosis Recruiting nowThis study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 08:14 UTC
-
Double radiation attack on resistant prostate cancer enters human testing
Disease control Recruiting nowThis is a phase I dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA small molecule. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates (radiation linked to antibodies/molecules that recognize pr…
Phase 1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Promising combo offers hope for elderly lymphoma patients
Disease control OngoingThis phase II trial studies the side effects of acalabrutinib and rituximab and its effect in treating patients with previously untreated mantle cell lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for teens with chronic migraines?
Disease control Recruiting nowTo find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Phase 3 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC